EP2303844A1 - Styrylquinolines, their process of preparation and their therapeutic uses - Google Patents

Styrylquinolines, their process of preparation and their therapeutic uses

Info

Publication number
EP2303844A1
EP2303844A1 EP09780982A EP09780982A EP2303844A1 EP 2303844 A1 EP2303844 A1 EP 2303844A1 EP 09780982 A EP09780982 A EP 09780982A EP 09780982 A EP09780982 A EP 09780982A EP 2303844 A1 EP2303844 A1 EP 2303844A1
Authority
EP
European Patent Office
Prior art keywords
hydroxy
vinyl
quinolin
compound
anyone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09780982A
Other languages
German (de)
French (fr)
Inventor
Bruno Giethlen
Mathieu Michaut
Claude Monneret
Emilienne Soma
Laurent Thibaut
Camille Georges Wermuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioalliance Pharma SA
Original Assignee
Bioalliance Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08161000A external-priority patent/EP2147912A1/en
Priority claimed from US12/269,241 external-priority patent/US20100120847A1/en
Application filed by Bioalliance Pharma SA filed Critical Bioalliance Pharma SA
Priority to EP09780982A priority Critical patent/EP2303844A1/en
Publication of EP2303844A1 publication Critical patent/EP2303844A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • a subject of the present invention is quinoline derivatives, in particular endowed with inhibitory properties of Human Immuno-deficiency Virus (HIV) integrase. It also relates to a synthetic process for these derivatives and their biological uses.
  • HIV Human Immuno-deficiency Virus
  • the replication cycle of HIV and other retroviruses involves three major viral enzymes: reverse transcriptase, protease and integrase. Integrase catalyzes the integration of the viral DNA into chromosomal DNA of the host infected cell, it is an essential step for the replication of HIV and other retroviruses. Consequently, an integrase inhibitor constitutes ipso facto an accurate candidate for blocking infection by HIV, and possibly an effective therapeutic agent.
  • Polytherapy targeting reverse transcriptase and/or protease and/or integrase is today the only method to effectively combat the rapid development of the virus.
  • HIV reverse transcriptase and protease are each targeted by about 10 therapeutic agents.
  • integrase is targeted by only one commercialized medication: the Merck's lsentress (raltegravir or MK-0518), approved by the U.S. Food and Drug Administration (FDA) in October 2007.
  • FDA U.S. Food and Drug Administration
  • a second integrase inhibitor, Gilead's elvitegravir (GS-9137) is in advanced clinical trials.
  • the integration of the viral DNA into the chromosomal DNA of the infected cells occurs through a two-steps process: (i) in the "3' processing step", integrase in the cytoplasm of the host cell removes a dinucleotide from 3' end of the viral DNA, while (ii) in the "strand transfer step”, integrase in the nucleus catalyzes the insertion of the processed 3' end viral DNA into the host cell DNA.
  • Integrase inhibitors can be divided into two groups: (i) inhibitors of the 3' processing (referred to as INBIs) and (ii) selective strand transfer inhibitors (referred to as INSTIs) (Pommier Y, and al. Nat Rev Drug Discov 2005, 4:236- 248).
  • INBIs act as docking at the HIV DNA-binding site, preventing 3' processing and strand transfer and INSTIs act as occupying the infected cells DNA-binding site, thus only preventing strand transfer (Johnson AA et al. MoI Pharmacol. 2007 71 (3):893-901 ).
  • Raltegravir and elvitegravir belong to the INSTIs group.
  • WO 98/45269 discloses phenyl substituted quinolines, in particular styryl quinolines, where the various positions of the quinoleine and phenyl moieties may be optionally substituted.
  • the inventors have now showed that the presence of a substituent on the 5- position of the quinoline moiety, combined with a 8-OH on the quinoline core surprisingly leads to substantially increased properties, such as their antiviral efficacy, their stability, and/or their biodisponibility.
  • quinoline derivatives may present a low solubility
  • the inventors have designed suitable formulations of the compounds of the invention, allowing satisfying solubility.
  • the quinoline derivatives of the invention are moreover efficient against INSTIs resistant integrase.
  • the quinoline derivatives of the invention are particularly useful for inhibiting Raltegravir and/or Elvitegravir resistant integrase.
  • Another object of the invention is the combination of said quinoline derivatives with other anti viral agent(s). Indeed, said combinations, in particular those of quinoline derivatives with INSTIs or reverse transcriptase inhibitors, show synergistic effects.
  • the derivatives according to the invention are characterized in that they correspond to the general formula (I) :
  • - X represents a group chosen from a halogen atom, -OH, -OR, -COH, -COR, -COOH, -COOR, -NO 2 , CN; more preferably -COH, -COR, -OH or -NO 2 ; and/or
  • R4, R5, R6, R7, R8 are distinct of H;
  • R4, R5, R6, R7, R8 is OH; and/or - R6 is OH; and/or
  • Y is -COR;
  • the compounds of the invention are chosen from : - 1 - ⁇ 2-[2(E)-(3-chloro, 4,5-dihydroxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl ⁇ - ethanone;
  • Halo or halogen refers to fluorine, chlorine, bromine or iodine atom.
  • Alkyl represents an aliphatic-hydrocarbon group which may be straight or branched, having 1 to 20 carbon atoms in the chain unless specified otherwise. Preferred alkyl groups have 1 to 12 carbon atoms, more preferably have 1 to 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl.
  • Aryl refers to an aromatic monocyclic or multicyclic hydrocarbon ring system of 6 to 14 carbon atoms, preferably of 6 to 10 carbon atoms.
  • exemplary aryl groups include phenyl, naphthyl, indenyl, phenanthryl, biphenyl.
  • heterocycle or “heterocyclic” refer to a saturated or partially unsaturated non aromatic stable 3 to 14, preferably 5 to 10-membered mono, bi or multicyclic rings, wherein at least one member of the ring is a hetero atom.
  • heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, selenium, and phosphorus atoms.
  • Preferable heteroatoms are oxygen, nitrogen and sulfur.
  • Suitable heterocycles are also disclosed in the Handbook of Chemistry and Physics, 76th Edition, CRC Press, Inc., 1995-1996, pages 2-25 to 2-26, the disclosure of which is hereby incorporated by reference.
  • Preferred non aromatic heterocyclic include, but are not limited to oxetanyl, tetraydrofuranyl, dioxolanyl, tetrahydropyranyl, dioxanyl, pyrrolidinyl, piperidyl, morpholinyl, imidazolidinyl, pyranyl.
  • Preferred aromatic heterocyclic, herein called heteroaryl groups include, but are not limited to, pyridyl, pyridyl- ⁇ /-oxide, pyrimidinyl, pyrrolyl, imidazolinyl, pyrrolinyl, pyrazolinyl, furanyl, thienyl, imidazolyl, triazolyl, tetrazolyl, quinolyl, isoquinolyl, benzoimidazolyl, thiazolyl, pyrazolyl, and benzothiazolyl groups.
  • Alkyl also refers to the corresponding “alkylene”, “arylene”, “heterocyclene” which are formed by the removal of two hydrogen atoms.
  • the compounds herein described may have asymmetric centers.
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded and that the substitution results in a stable compound.
  • patient refers to a warm-blooded animal such as a mammal, preferably a human or a human child, which is afflicted with, or has the potential to be afflicted with one or more diseases and conditions described herein.
  • a "therapeutically effective amount” refers to an amount of a compound of the present invention which is effective in reducing, eliminating, treating or controlling the symptoms of the herein-described diseases and conditions.
  • controlling is intended to refer to all processes wherein there may be a slowing, interrupting, arresting, or stopping of the progression of the diseases and conditions described herein, but does not necessarily indicate a total elimination of all disease and condition symptoms, and is intended to include prophylactic treatment and chronic use.
  • pharmaceutically acceptable refers to those compounds, materials, compositions, or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, tartaric, citric, methanesulfonic, benzenesulfonic, glucoronic, glutamic, benzoic, salicylic, toluenesulfonic, oxalic, fumaric, maleic, and the like.
  • Further addition salts include ammonium salts such as tromethamine, meglumine, epolamine, etc., metal salts such as sodium, potassium, calcium, zinc or magnesium.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoechiomethc amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
  • non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418 and P. H. Stahl, CG. Wermuth, Handbook of Pharmaceutical salts - Properties, Selection and Use, Wiley-VCH, 2002, the disclosures of which are hereby incorporated by reference.
  • the invention also relates to a synthetic process for the derivatives defined above.
  • the compounds of formula (I) may be prepared in a number of ways well- known to those skilled in the art. In particular, they may be synthesized by application or adaptation of the process of preparation disclosed in WO 98/45269, or variations thereon as appreciated by the skilled artisan. The appropriate modifications and substitutions will be readily apparent and well-known or readily obtainable from the scientific literature to those skilled in the art.
  • the compounds of the present invention may contain one or more asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms.
  • optically active or racemic forms all chiral, diastereomehc, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well- known in the art how to prepare and isolate such optically active forms.
  • mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers.
  • bases include: sodium hydroxide, potassium carbonate, thethylamine, alkali metal hydrides, such as sodium hydride and potassium hydride; alkyllithium compounds, such as methyllithium and butyllithium; and alkali metal alkoxides, such as sodium methoxide and sodium ethoxide.
  • reaction are carried out in a suitable solvent.
  • solvents may be used, provided that it has no adverse effect on the reaction or on the reagents involved.
  • suitable solvents include: hydrocarbons, which may be aromatic, aliphatic or cycloaliphatic hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene; amides, such as dimethyl-formamide; alcohols such as ethanol and methanol and ethers, such as diethyl ether and tetrahydrofuran.
  • the reactions can take place over a wide range of temperatures.
  • reaction it is convenient to carry out the reaction at a temperature of from OO to 150O (more preferably from about room temperature to 100O).
  • the time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 20 hours will usually suffice.
  • the process of the invention is characterized in that it comprises the reaction of a quinaldine of formula (II) :
  • R2 ⁇ R4 ⁇ R5 ⁇ R6 ⁇ R7 ⁇ R8 ⁇ X' are defined as R1 , R2, R4, R5, R6, R7, R8, X above, provided any reactive function present in R1 , R2, R4, R5, R6, R7, R8, X may be protected by an appropriate protective group in R1 ', R2', R4', R5 ⁇ R6 ⁇ R7', R8 ⁇ X' respectively, and where Pg denotes either H or a protective group of the OH function if required, followed by the deprotection of any protective group present as appropriate.
  • the coupling may be advantageously conducted in an organic solvent, such as acetic anhydride and/or a mixture of pyhdine/water.
  • the reaction may be carried out at a temperature comprised between the room temperature and the boiling temperature of the reacting mixture.
  • OH groups may be protected in the form of acetoxy groups.
  • the deprotection may be conducted by hydrolysis.
  • the derivatives used as starting products in these syntheses are commercially available or easily accessible by synthesis for a person skilled in the art.
  • the derivatives of formula (II) may be synthesized in accordance with Meek et al., J. Chem. Engineering data, 1969, 14, 388-391 or Przystal et al, J.Heterocycl. Chem, 1967, 4, 131 -2.
  • the compounds of formula (III) are generally commercially available. If desired, the salts of the compounds of formula (I) may be obtained by adding the appropriate base or acid. For instance, where compounds of formula (I) comprise an acid function the sodium salt may be obtained by adding sodium hydroxide.
  • the process of the invention may also include the additional step of isolating the obtained product of formula (I).
  • the compound thus prepared may be recovered from the reaction mixture by conventional means.
  • the compounds may be recovered by distilling off the solvent from the reaction mixture or, if necessary after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract.
  • the product can, if desired, be further purified by various well known techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography.
  • the invention thus relates to pharmaceutical compositions characterized in that they contain an effective quantity of at least one derivative as defined above, in combination with pharmaceutically acceptable vehicles.
  • the present invention concerns formulations of a compound of formula (I) suitable for oral administration.
  • Said formulation may comprise one or more excipient(s) chosen from surfactant, emulsifier, solubility enhancers, etc...
  • the compounds of the invention are advantageously used in combination with other anti-viral agents, such as HIV medicaments, in particular medicaments endowed with an inhibitory effect vis-a-vis the integrase, reverse transcriptase and/or protease.
  • the compounds of the invention are active on resistant viruses, in particular viruses resistant to reverse transcriptase inhibitors and/or to INSTI integrase inhibitors.
  • the present invention thus also concerns such combinations of a compound of the invention with one or more integrase, reverse transcriptase and/or protease inhibitor(s), in particular, combinations of a compound of the invention with one or more INSTI inhibitor, such as raltegravir or elvitegravir.
  • the doses and administration methods are adapted as a function of the single-drug, two-drug or three-drug combination therapy treatment used.
  • the invention also relates to the use of the derivatives defined above as biological reagents usable in particular for mechanism studies concerning the viral infection.
  • the compounds of the invention may be advantageously used for inhibiting INSTIs resistant integrase.
  • a therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the therapeutically effective amount, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of subject; its size, age, and general health; the specific disease involved; the degree of involvement or the severity of the disease; the response of the individual subject; the particular compound administered; the mode of administration; the bioavailability characteristic of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
  • the amount of a compound of formula (I), which is required to achieve the desired biological effect will vary depending upon a number of factors, including the dosage of the drug to be administered, the chemical characteristics (e.g. hydrophobicity) of the compounds employed, the potency of the compounds, the type of disease, the diseased state of the patient, and the route of administration.
  • the compounds of this invention may be provided in an aqueous physiological buffer solution containing 0.1 to 10% w/v compound for parenteral and/or oral administration.
  • Typical dose ranges are from 1 ⁇ g/kg to 0.1 g/kg of body weight per day; a preferred dose range is from 0.01 mg/kg to 10 mg/kg of body weight per day.
  • a preferred daily dose for adult humans includes 1 , 5, 50, 100 and 200 mg, and an equivalent dose in a human child.
  • the preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, and formulation of the compound excipient, and its route of administration.
  • unit dose means a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described hereinafter.
  • typical daily dose ranges are from 0.01 to 10 mg/kg of body weight.
  • unit doses for humans range from 0.1 mg to 1000 mg per day.
  • the unit dose range is from 1 to 500 mg administered one to four times a day, and even more preferably from 1 mg to 300 mg, once a day.
  • compositions can be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients.
  • Such compositions may be prepared for use in oral administration, particularly in the form of tablets or capsules; or parenteral administration, particularly in the form of liquid solutions, suspensions or emulsions; or intranasally, particularly in the form of powders, nasal drops, or aerosols; or dermally, for example, topically or via trans-dermal patches or ocular administration, or intravaginal or intra-utehne administration, particularly in the form of pessaries or by rectal administration.
  • compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington: The Science and Practice of Pharmacy, 20 th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000.
  • Pharmaceutically compatible binding agents and/or adjuvant materials can be included as part of the composition.
  • Oral compositions will generally include an inert diluent carrier or an edible carrier.
  • the tablets, pills, powders, capsules, troches and the like can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, or gum tragacanth; a diluent such as starch or lactose; a disintegrant such as starch and cellulose derivatives; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, or methyl salicylate.
  • a binder such as microcrystalline cellulose, or gum tragacanth
  • a diluent such as starch or lactose
  • a disintegrant such as starch and cellulose derivatives
  • a lubricant such as magnesium stearate
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such as sucrose or saccharin
  • a flavoring agent
  • Capsules can be in the form of a hard capsule or soft capsule, which are generally made from gelatin blends optionally blended with plasticizers, as well as a starch capsule.
  • dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
  • Other oral dosage forms syrup or elixir may contain sweetening agents, preservatives, dyes, colorings, and flavorings.
  • the active compounds may be incorporated into fast dissolve, modified-release or sustained-release preparations and formulations, and wherein such sustained-release formulations are preferably bi-modal.
  • Preferred formulations include pharmaceutical compositions in which a compound of the present invention is formulated for oral or parenteral administration, or more preferably those in which a compound of the present invention is formulated as a tablet.
  • Preferred tablets contain lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or talc in any combination. It is also an aspect of the present disclosure that a compound of the present invention may be incorporated into a food product or a liquid.
  • Liquid preparations for administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • the liquid compositions may also include binders, buffers, preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like.
  • Non-aqueous solvents include alcohols, propylene glycol, polyethylene glycol, acrylate copolymers, vegetable oils such as olive oil, and organic esters such as ethyl oleate.
  • Aqueous carriers include mixtures of alcohols and water, hydrogels, buffered media, and saline.
  • biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the release of the active compounds.
  • Intravenous vehicles can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like.
  • Other potentially useful parenteral delivery systems for these active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
  • formulations for inhalation which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
  • Formulations for buccal administration include, for example, lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate.
  • Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate.
  • Formulations for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
  • Carriers which can be used include petroleum jelly, lanolin, polyethylene glycols, alcohols, or their combinations.
  • Formulations suitable for transdermal administration can be presented as discrete patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
  • Alternative administrations include also solutions, ointments or other formulations acceptable for ocular administration.
  • the compound of the invention may be administered by the cutaneous, ocular or inhalation route as disclosed above.
  • formulations are particularly advantageous as they ensure a local treatment, without associated lymphopenia which may occur with systemic administration routes.
  • Figure 1 illustrates the cross-resistance assay results obtained with a compound of the invention on INSTIs mutants.
  • Figure 2 illustrates the cross-resistance assay results obtained with a compound of the invention on RTIs mutants.
  • the pET-15b-IN plasmid contains the cDNA encoding the HBX2 HIV integrase. His-tagged integrase protein was overexpressed in Escherichia coli BL21 (DE3) and purified under native conditions. Briefly, at an OD of 0.8, fusion protein expression was induced in bacterial cultures by the addition of IPTG (1 mM). Cultures were incubated for 3 h at 37O, af ter which cells were centhfuged.
  • the cell pellet was resuspended in ice-cold buffer A [20 mM Ths-HCI (pH 8), 1 M NaCI, 4 mM ⁇ -mercaptoethanol, and 5 mM imidazole], treated with lysozyme for 1 h on ice, and sonicated. After centhfugation (30 min at 10 000 rpm), the supernatant was filtered (0.45 ⁇ m) and incubated for at least 2 h with Ni- NTA agarose beads (Pharmacia). The beads were washed twice with 10 volumes of buffer A, 10 volumes of buffer A with 50 mM imidazole, and 10 volumes of buffer A with 100 mM imidazole.
  • His-tagged integrase was then eluted with buffer A supplemented with 50 ⁇ M ZnSO4 and 1 M imidazole. The integrase concentration was adjusted to 0.1 mg/mL in buffer A. The fusion protein was cleaved using thrombin and dialyzed overnight against 20 mM Ths-HCI (pH 8), 1 M NaCI, and 4 mM ⁇ -mercaptoethanol.
  • Oligonucleotides U5B ( ⁇ '-GTGTGGAAAATCTCTAGCAGT-S 1 ), U5B-2 (5 1 - GTGTGGAAAATCTCTAGCA-3'), U5A ( ⁇ '-ACTGCTAGAGATTTTCCACAC-S 1 ) were purchased from Eurogentec (Liege, Belgium) and further purified on an 18% denaturing acrylamide/urea gel.
  • strand transfer 100 pmol of U5B, U5B-2, respectively, were radiolabeled using T4 polynucleotide kinase and 50 ⁇ Ci of [ ⁇ -32P]ATP (3000 Ci/mmol).
  • T4 kinase was heat inactivated, and unincorporated nucleotides were removed using a Sephadex G-10 column (GE Healthcare). NaCI was added to a final concentration of 0.1 M, and complementary unlabeled strand U5A was added to either U5B or U5B-2. The mixture was heated to 90O fOr S min, and the DNA w as annealed by slow cooling.
  • strand transfer reactions were performed using U5A-U5B-2, in buffer containing 20 mM Tris (pH 7.2), 50 mM NaCI, 10 mM DTT, 1 OmM MgCI 2 .
  • the reaction was initiated by addition of substrate DNA (12.5 nM), IN 20OnM and the mixture was incubated for up to 2 h at 37O. Th e reaction was stopped by phenol/chloroform extraction, and DNA products were precipitated with ethanol.
  • the products were separated in TE containing 7 M urea and electrophoresed on an 18% denaturing acrylamide/urea gel. Gels were analyzed using a STORM Molecular Dynamics phosphorimager and quantified with Image QuantTM 4.1 software.
  • Hepes Buffer 0.5M, pH 7.5. 16 ⁇ l of drug at 25 mM, in 8 ml of Hepes Buffer. Different time points were done, Oh, 2h, 4h, 24h, and 48h.
  • the second stability assay consists in the assessment according to standard HPLC analysis protocols over 24 hrs in PEG400 and Vitamine E- TPGS/PEG 400 mixtures, by focusing on the evolution of the concentration and peak purity of the compound.
  • a mobile phase of water/acetic acid 0.1 % (Solvant A) : Acetonitrile/acetic acid 0.1 % (solvent B) mixture or a water/trifluoroacetic acid 0.1 % (Solvant A) : Acetonitrile/ trifluoroacetic acid 0.1 % (solvent B) mixture in the case of compound FZ41 was pumped according to a binary gradient described below, at a flow rate of 0.4 ml/min.
  • the compounds of the invention demonstrated high stability over 24 hrs at room temperature in several mixtures of excipients with less than 10% degradation, whereas FZ41 exhibited at least 10% degradation within only 3 hrs, as stated by the apparition of impurity peaks.
  • CEM cell were obtained from the American Type Tissue Collection (Rockville, MD).
  • a serial dilution of drugs is done to evaluate the cytotoxicity concentration and is identified by CC50 (concentration of drug which induces 50% of cytotoxicity)
  • the Hel_a-P4 was cultured in the presence or absence of compounds for 2 days. After this time period, cells were cultivated with MTT for 3 hours, further the medium is removed. And the lysis buffer is incubated for 1 hour, followed by plate reading at 540 nm in a microplate reader.
  • the antiviral activity is determined by infecting HelaP4 cells with a wild type HIV-1 virus (NL 4.3 strains at 3ng) on cells in presence or absence of drugs.
  • the effective concentration is the concentration of product at which virus replication is inhibited by 50 percent.
  • the quantification is done by the evaluation of ⁇ - Galactosidase produced by the infected HeIa P4 cells.
  • the viral activity is evaluated by colorimethc assay, CPRG, followed by plate reading at 570 nm with a reference of 690 nm.
  • the CPRG test is a colohmetric assay which allows to quantity the ⁇ -galactosidase produced by HIV-1 infected indicator cells (the ⁇ -Gal gene being under the control of the HIV-1 LTR).
  • the activity is determined by infecting CEM cells with a wild type HIV-1 virus (NL 4.3 strains at 3ng) on cells in presence or absence of drugs.
  • the effective concentration is the concentration of product at which virus replication is inhibited by 50 percent.
  • the quantification is done by the evaluation of the viral protein p24 with a commercial Elisa Kit.
  • P24 is a protein essential to the replication virus cycle. The quantification of this enzyme is proportional to the amount of virus produced by the infected cells.
  • Antiviral products targeting the same protein may develop mutations that lead to reduced susceptibility to one antiviral product and can result in decreased or loss of susceptibility to other antiviral products in the same drug class. This observation is referred to as cross- resistance. Cross-resistance is not necessarily reciprocal, so it is important to evaluate the activity of our new compounds on viruses containing mutations observed with other drugs of the anti-integrase class or reverse transcriptase inhibitors (RTI) class.
  • RKI reverse transcriptase inhibitors
  • Mutant viruses which are Raltegravir & Elvitegravir resistant were constructed on the NL43 backbone. Mutants viruses were as followed, where the first letter corresponds to the wild type amino acid, the number corresponds to the position of the amino acid in the integrase sequence and the second letter corresponds to the mutated amino acid. NL4.3 E92Q,
  • Resistant mutant viruses of RTI include K103N, Y178L, Y181 C, G190A, V108I/Q151 M, K103N/G190A, K103N/Y188C, K103N/Y181 C, M41 L/T215Y/K103N, M41 L/T215Y/Y181 C, M41 L/T215Y/M184V.
  • the assay to evaluate the activity against resistant viral strains is the same that antiviral assay. Instead of using a Wild-type virus, the virus studied contains mutations. The results are presented as a fold change corresponding to the ratio between the IC50 obtained for the mutant virus and the IC50 obtained for the wild type virus. More the virus is resistant to the compound more the fold change is elevated. If the mutation has no impact on the activity of the drug, the fold change is around 1.
  • a combination manifests therapeutic synergy if it is therapeutically superior to the addition of the therapeutic effects of the independent constituents.
  • the efficacy of a combination may be demonstrated by comparing the IC50 values of the combination with the IC50 values of each of the separate constituents in the study in question. This efficacy may be readily determined by the one skilled in the art.
  • a combination index (Cl) may be calculated, for instance using the computer program CalcuSyn software from Biosoft, for inhibition efficiencies of 50%, 75% or 90%.
  • the program CalcuSyn performs multiple drug dose-effect calculations using the Median Effect methods described by Chou et al Trends Pharmacol. Sci. 4:450-454, 1983 and Chou et al Enzyme Regul. 22, 27-55, 198', which are incorporated herein by reference.
  • the combination index (Cl) equation is based on the multiple dose effect equation of Chou et al derived from enzyme kinetics model.
  • the synergism is defined as a more than expected additive effect and antagonism as a less than expected additive effect.
  • (D1 ) and (D2) are the concentrations of drug 1 and 2, respectively, for which x % of inhibition is obeyed in the drug combination.
  • (Dx1 ) and (Dx2) are the concentrations of drug 1 and 2 respectively for which x % of inhibition is obeyed for drugs alone.
  • Synergistic interactions between compounds of the invention (SQE94) and INSTI (Raltegravir or RGV) were investigated using a NL43 HIV-1 laboratory strain replication assay. Virus infectivity in the presence of inhibitors was monitored with HelaCD4+ ⁇ -Gal indicator cells (P4 cells). Inhibition by combination of SQE94 and INSTI was evaluated at two fixed molar SQE94/ INSTI ratios: (i) 100:1 when the combination is tested on wild type virus and (ii) 6:1 when the combination is tested on INSTI resistant virus.
  • Step 1 preparation of HeLa P4 cells in a 96 flat bottom well plate
  • HeLa P4 cells per well are seeded in 100 ⁇ l of 10% FBS DMEM supplemented with 100UI/ml penicillin, 100 ⁇ g/ml streptomycin and 0.5 mg/ml geneticin (G418).
  • One plate is used for the 2 drugs alone.
  • Half a plate is used for the combination between the two drugs.
  • the cytotoxicity of the drugs alone and the combination is tested by MTT assay.
  • Step 2 Drug dilution
  • the dilutions tested for the "Wild type" virus are as follows: 16IC 5 o -> 8IC50 ⁇ 4IC 50 ⁇ 2IC 50 - ⁇ 1 IC 50 ⁇ * ICso/2 ⁇ IC 50 M-* IC 50 /8 ⁇ IC 50 /16 ⁇ IC 50 /32 Drugs alone :
  • the dilutions tested for the "INSTI's Mutants" virus are as follows: 60IC 50 -» 20IC 50 ⁇ 6,7IC 50 ⁇ 2,2IC 50 ⁇ 0,74IC 50 -» 0.25IC 50 ⁇ 0.08IC 50 ⁇ 0.03IC 50 ⁇ 0.009IC 50 ⁇ 0.003IC 50
  • Quinoline derivatives may present a low solubility in aqueous buffers at pH 5, 6 and 7. Two formulations were identified to solve this drawback:
  • Formulation A Tween 80/Labrafac® Lipophile/DMSO: 65/25/10
  • Formulation B Tween 80/Labrafil ® M1944 CS/DMSO: 65/25/10
  • Labrafil® and Labrafac® are solubility enhancers;
  • Labrafil® M1944 CS comprises Oleoyl Macrogolglycerides (Polyoxylglycehdes) and Labrafac® Lipophile is a mixture of Medium Chain Triglycerides.
  • LabrafacTM Lipophile WL 1349 and Labrafil M1944 CS are purchased from Gattefosse (France).
  • Solubility of compound SQE94 was determined in pH-buffers at pH values of 5, 6 and 7. 10 mg of SQE94 are added to 10 ml of each pH-buffer. Each solution is stirred at room temperature, away from light, for 24h, then centrifugated. The amount of dissolved compound is determined by HPLC analysis.
  • Solubility of compound SQE94 was determined in formulation A and B. 50 mg of product is dissolved in 5 mL of formulation and stirred at 37O for 24h, then centrifugated. The amount of dissolved compound is determined by HPLC analysis.
  • Formulated compound SQE94 (in formulation A or B) is diluted 1/10e with 37O pH-buffers (pH 5,6 and 7). Samples are immedia tely collected and centhfuged. The amount of dissolved compound is determined by HPLC analysis.
  • Formulation A and B enable to increase the solubility of compound SQE94 at pH 5, 6 and 7 by at least a 80-fold. These pHs mimic the pH within the intestinal tractus, where the maximum of absorption of a drug takes place. Results are summarized in following table : Dissolved Dompound SQE94 ( ⁇ g/ml)
  • Formulations A and B show good solubility, suitable to oral formulation of quinoline derivatives of the invention.

Abstract

The present invention concerns new substituted styrylquinolines, their process of preparation and their therapeutic uses as integrase inhibitors and/or for the treatment and/or prevention of HIV.

Description

STYRYLQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES
A subject of the present invention is quinoline derivatives, in particular endowed with inhibitory properties of Human Immuno-deficiency Virus (HIV) integrase. It also relates to a synthetic process for these derivatives and their biological uses.
The replication cycle of HIV and other retroviruses involves three major viral enzymes: reverse transcriptase, protease and integrase. Integrase catalyzes the integration of the viral DNA into chromosomal DNA of the host infected cell, it is an essential step for the replication of HIV and other retroviruses. Consequently, an integrase inhibitor constitutes ipso facto an accurate candidate for blocking infection by HIV, and possibly an effective therapeutic agent.
Polytherapy targeting reverse transcriptase and/or protease and/or integrase is today the only method to effectively combat the rapid development of the virus. Currently, HIV reverse transcriptase and protease are each targeted by about 10 therapeutic agents. However, integrase is targeted by only one commercialized medication: the Merck's lsentress (raltegravir or MK-0518), approved by the U.S. Food and Drug Administration (FDA) in October 2007. A second integrase inhibitor, Gilead's elvitegravir (GS-9137), is in advanced clinical trials.
The integration of the viral DNA into the chromosomal DNA of the infected cells occurs through a two-steps process: (i) in the "3' processing step", integrase in the cytoplasm of the host cell removes a dinucleotide from 3' end of the viral DNA, while (ii) in the "strand transfer step", integrase in the nucleus catalyzes the insertion of the processed 3' end viral DNA into the host cell DNA.
Integrase inhibitors can be divided into two groups: (i) inhibitors of the 3' processing (referred to as INBIs) and (ii) selective strand transfer inhibitors (referred to as INSTIs) (Pommier Y, and al. Nat Rev Drug Discov 2005, 4:236- 248). INBIs act as docking at the HIV DNA-binding site, preventing 3' processing and strand transfer and INSTIs act as occupying the infected cells DNA-binding site, thus only preventing strand transfer (Johnson AA et al. MoI Pharmacol. 2007 71 (3):893-901 ). Raltegravir and elvitegravir belong to the INSTIs group. However, a limit of these inhibitors is the high rate of virus mutations in treated patients leading to INSTIs resistance. It is thus a substantial advantage to identify a potent inhibitor of the 3' processing step of integrase with a specific mechanism of action leading to the inhibition of the both steps of integration. Moreover this kind of inhibitors could remain still active on virus bearing mutations which lead to INSTIs resistance.
The inventors have studied quinoline derivatives and have demonstrated anti-integrase properties in vitro as well as in vivo, these properties being accompanied by significant innocuity. WO 98/45269 discloses phenyl substituted quinolines, in particular styryl quinolines, where the various positions of the quinoleine and phenyl moieties may be optionally substituted.
The inventors have now showed that the presence of a substituent on the 5- position of the quinoline moiety, combined with a 8-OH on the quinoline core surprisingly leads to substantially increased properties, such as their antiviral efficacy, their stability, and/or their biodisponibility.
Noteworthy, their stability is particularly advantageous. Indeed, styryl quinolines disclosed in WO 98/45269 showed poor stability, thus constituting a major drawback for further drug development.
Moreover, it is particularly desirable to provide drug candidates with satisfying solubility, in particular in aqueous medium at the pH of the intestinal tractus, to allow administration by oral route. Although, quinoline derivatives may present a low solubility, the inventors have designed suitable formulations of the compounds of the invention, allowing satisfying solubility.
Further, the quinoline derivatives of the invention are moreover efficient against INSTIs resistant integrase. Noteworthy, the quinoline derivatives of the invention are particularly useful for inhibiting Raltegravir and/or Elvitegravir resistant integrase. Another object of the invention is the combination of said quinoline derivatives with other anti viral agent(s). Indeed, said combinations, in particular those of quinoline derivatives with INSTIs or reverse transcriptase inhibitors, show synergistic effects. The derivatives according to the invention are characterized in that they correspond to the general formula (I) :
wherein : - R1 , R2, R4, R5, R6, R7, R8 identical or different, independently represent a hydrogen atom or a group chosen from -(CH2)n-Y or -CH=CH-Y, where Y represents a halogen atom, -OH, -OR, -COH, -COR, -COOH, -COOR, -CONH2, -CON(Rx1Ry), -CH=NOH, -CO-CH=NOH, -NH2, -N(Rx1Ry), -NO2, -PO(OR)2, -PO(OH)2, -C(=O)-NH-OH, -SH2, -SR, -SO2R, -SO2NHR, CN, - X represents a group chosen from -(CH2)n-Y or -CH=CH-Y, where Y represents a halogen atom, -OH, -OR, -COH, -COR, -COOH, -COOR, -CONH2, -CON(Rx1Ry), -CH=NOH, -CO-CH=NOH, -NH2, -N(Rx1Ry), -NO2, -PO(OR)2, -PO(OH)2, -C(=O)-NH-OH, -SH2, -SR, -SO2R, -SO2NHR, CN, where R represents an alkyl, or an aryl or heterocycle, Rx and Ry, identical or different represent an alkyl, and n is an integer chosen from O, 1 to 5; as well as their pharmaceutically acceptable salts, their diastereoisomers and enantiomers.
The present invention also encompasses the following preferred embodiments and any of their combinations:
- X represents a group chosen from a halogen atom, -OH, -OR, -COH, -COR, -COOH, -COOR, -NO2, CN; more preferably -COH, -COR, -OH or -NO2; and/or
- R1 and R2 are H; and/or - R1 , R2, R3, R4, R5, R6, R7, R8 identical or different, independently represent a hydrogen atom or a halogen atom or a group chosen from -OH, -OR, -COH, -COR, -COOH, -COOR, -NO2, -PO(OR)2, -PO(OH)2, -C(=O)-NH-OH, CN; more preferably chosen from a hydrogen atom, halogen atom or a group chosen from -OH, -OR, -COH, -COR, -COOH, -COOR, -NO2; still more preferably chosen from a hydrogen atom, or a group chosen from -OH, -COR, -COOH, -NO2, and/or
- two or three of R4, R5, R6, R7, R8 are distinct of H; and/or
- at least one of R4, R5, R6, R7, R8 is OH; and/or - R6 is OH; and/or
- X represents a group chosen from -(CH2)n-Y or -CH=CH-Y, where Y represents -OH, -OR, -COH, -COR, -COOR, -CONH2, -CON(Rx1Ry), -CH=NOH,
-CO-CH=NOH, -NH2, -N(Rx1Ry), -PO(OR)2, -PO(OH)2, -C(=O)-NH-OH, -SH2, -SR, -SO2R, -SO2NHR, CN, more preferably, Y is -COR; and/or
- R1 =R2=H; and/or . R4=R8=H, and/or
- At least one of R5, R7 is chosen from a halogen atom or a group chosen from -COH, -COR, -COOH, -COOR, -NO2, -PO(OR)2, -PO(OH)2, -C(=O)-NH-OH, CN; more preferably chosen from a halogen atom or a
-NO2.
Preferably, the compounds of the invention are chosen from : - 1 -{2-[2(E)-(3-chloro, 4,5-dihydroxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone;
- 5-[2(E)-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-2-hydroxy-benzoic acid ;
- 1 -{2-[2(E)-(2,3-Dihydroxy-4-methoxy-phenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone; - 1 -{2-[2(E)-(2,4,5-thhydroxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl}-ethanone; - 1 -{2-[2(E)-(3,4,5-thhydroxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl}-ethanone ;
- 1 -{2-[2(E)-(3,4-dihydroxy, 5-nitrophenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone ;
- 1 -{2-[2(E)-(4-hydroxy, 5-methoxy, 3-nitrophenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone ;
- 4-[2(E)-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-5-nitro-benzoic acid; - 4-[(E)-2-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-3-nitro-benzoic acid methyl ester ;
- 3-[(E)-2-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-4-nitro-benzoic acid methyl ester; - 5-[2(E)-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-2-hydroxy-4-nitro-benzoic acid ;
- 1 -{2-[2(E)-(3-nitro, 4-hydroxy, 5-methoxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone ;
- 1 -{2-[2(E)-(3,4-dihydroxy, 5-methoxyphenyl)-vinyl]-7-chloro, 8-hydroxy-quinolin-5- yl}-ethanone ; as well as their pharmaceutically acceptable salts, their diastereoisomers and enantiomers.
Unless specified otherwise, the terms used hereabove or hereafter have the meaning ascribed to them below: "Halo" or "halogen" refers to fluorine, chlorine, bromine or iodine atom.
"Alkyl" represents an aliphatic-hydrocarbon group which may be straight or branched, having 1 to 20 carbon atoms in the chain unless specified otherwise. Preferred alkyl groups have 1 to 12 carbon atoms, more preferably have 1 to 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl.
"Aryl" refers to an aromatic monocyclic or multicyclic hydrocarbon ring system of 6 to 14 carbon atoms, preferably of 6 to 10 carbon atoms. Exemplary aryl groups include phenyl, naphthyl, indenyl, phenanthryl, biphenyl.
The terms "heterocycle" or "heterocyclic" refer to a saturated or partially unsaturated non aromatic stable 3 to 14, preferably 5 to 10-membered mono, bi or multicyclic rings, wherein at least one member of the ring is a hetero atom. Typically, heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, selenium, and phosphorus atoms. Preferable heteroatoms are oxygen, nitrogen and sulfur. Suitable heterocycles are also disclosed in the Handbook of Chemistry and Physics, 76th Edition, CRC Press, Inc., 1995-1996, pages 2-25 to 2-26, the disclosure of which is hereby incorporated by reference.
Preferred non aromatic heterocyclic include, but are not limited to oxetanyl, tetraydrofuranyl, dioxolanyl, tetrahydropyranyl, dioxanyl, pyrrolidinyl, piperidyl, morpholinyl, imidazolidinyl, pyranyl. Preferred aromatic heterocyclic, herein called heteroaryl groups include, but are not limited to, pyridyl, pyridyl-Λ/-oxide, pyrimidinyl, pyrrolyl, imidazolinyl, pyrrolinyl, pyrazolinyl, furanyl, thienyl, imidazolyl, triazolyl, tetrazolyl, quinolyl, isoquinolyl, benzoimidazolyl, thiazolyl, pyrazolyl, and benzothiazolyl groups.
"Alkyl", "aryl", "heterocycle" also refers to the corresponding "alkylene", "arylene", "heterocyclene" which are formed by the removal of two hydrogen atoms.
The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well-known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Geometric isomers of double bonds such as olefins and C=N can also be present in the compounds described here, all the stable isomers are contemplated here. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a compound are intended, unless the stereochemistry or the isomeric form is specifically indicated. All processes used to synthesize the compounds of the present invention are considered as part of the present invention.
The term "substituted" as used herein means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded and that the substitution results in a stable compound. As used herein, the term "patient" refers to a warm-blooded animal such as a mammal, preferably a human or a human child, which is afflicted with, or has the potential to be afflicted with one or more diseases and conditions described herein.
As used herein, a "therapeutically effective amount" refers to an amount of a compound of the present invention which is effective in reducing, eliminating, treating or controlling the symptoms of the herein-described diseases and conditions. The term "controlling" is intended to refer to all processes wherein there may be a slowing, interrupting, arresting, or stopping of the progression of the diseases and conditions described herein, but does not necessarily indicate a total elimination of all disease and condition symptoms, and is intended to include prophylactic treatment and chronic use.
As used herein, the expression "pharmaceutically acceptable" refers to those compounds, materials, compositions, or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
As used herein, the expression "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, tartaric, citric, methanesulfonic, benzenesulfonic, glucoronic, glutamic, benzoic, salicylic, toluenesulfonic, oxalic, fumaric, maleic, and the like. Further addition salts include ammonium salts such as tromethamine, meglumine, epolamine, etc., metal salts such as sodium, potassium, calcium, zinc or magnesium. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoechiomethc amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418 and P. H. Stahl, CG. Wermuth, Handbook of Pharmaceutical salts - Properties, Selection and Use, Wiley-VCH, 2002, the disclosures of which are hereby incorporated by reference.
The compounds of the general formula (I) having geometrical and stereoisomers are also a part of the invention.
The invention also relates to a synthetic process for the derivatives defined above. The compounds of formula (I) may be prepared in a number of ways well- known to those skilled in the art. In particular, they may be synthesized by application or adaptation of the process of preparation disclosed in WO 98/45269, or variations thereon as appreciated by the skilled artisan. The appropriate modifications and substitutions will be readily apparent and well-known or readily obtainable from the scientific literature to those skilled in the art.
In particular, such methods can be found in R. C. Larock, Comprehensive Organic Transformations, VCH publishers, 1989 It will be appreciated that the compounds of the present invention may contain one or more asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms. Thus, all chiral, diastereomehc, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well- known in the art how to prepare and isolate such optically active forms. For example, mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers.
Compounds of the present invention may be prepared by a variety of synthetic routes. The reagents and starting materials are commercially available, or readily synthesized by well-known techniques by one of ordinary skill in the arts. All substituents, unless otherwise indicated, are as previously defined.
In the reactions described hereinafter, it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P. G. M. Wuts in Protective Groups in Organic Synthesis, John Wiley and Sons, 1991 ; J. F. W. McOmie in Protective Groups in Organic Chemistry, Plenum Press, 1973. Some reactions may be carried out in the presence of a base. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used in reactions of this type may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: sodium hydroxide, potassium carbonate, thethylamine, alkali metal hydrides, such as sodium hydride and potassium hydride; alkyllithium compounds, such as methyllithium and butyllithium; and alkali metal alkoxides, such as sodium methoxide and sodium ethoxide.
Usually, reactions are carried out in a suitable solvent. A variety of solvents may be used, provided that it has no adverse effect on the reaction or on the reagents involved. Examples of suitable solvents include: hydrocarbons, which may be aromatic, aliphatic or cycloaliphatic hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene; amides, such as dimethyl-formamide; alcohols such as ethanol and methanol and ethers, such as diethyl ether and tetrahydrofuran. The reactions can take place over a wide range of temperatures. In general, it is convenient to carry out the reaction at a temperature of from OO to 150O (more preferably from about room temperature to 100O). The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 20 hours will usually suffice.
The process of the invention is characterized in that it comprises the reaction of a quinaldine of formula (II) :
(II) with a compound of formula (III):
where RT, R2\ R4\ R5\ R6\ R7\ R8\ X' are defined as R1 , R2, R4, R5, R6, R7, R8, X above, provided any reactive function present in R1 , R2, R4, R5, R6, R7, R8, X may be protected by an appropriate protective group in R1 ', R2', R4', R5\ R6\ R7', R8\ X' respectively, and where Pg denotes either H or a protective group of the OH function if required, followed by the deprotection of any protective group present as appropriate.
The coupling may be advantageously conducted in an organic solvent, such as acetic anhydride and/or a mixture of pyhdine/water. The reaction may be carried out at a temperature comprised between the room temperature and the boiling temperature of the reacting mixture.
Generally, OH groups may be protected in the form of acetoxy groups. The deprotection may be conducted by hydrolysis.
The derivatives used as starting products in these syntheses are commercially available or easily accessible by synthesis for a person skilled in the art. Thus, for example, the derivatives of formula (II) may be synthesized in accordance with Meek et al., J. Chem. Engineering data, 1969, 14, 388-391 or Przystal et al, J.Heterocycl. Chem, 1967, 4, 131 -2. As a representative example, the compound of formula (II) where R1 =R2=H and X is -COR may be obtained by reacting the corresponding compound of formula (II) where R1 =R2=X=H, with a compound of formula X-HaI, where Hal represents a halogen atom.
The compounds of formula (III) are generally commercially available. If desired, the salts of the compounds of formula (I) may be obtained by adding the appropriate base or acid. For instance, where compounds of formula (I) comprise an acid function the sodium salt may be obtained by adding sodium hydroxide.
The process of the invention may also include the additional step of isolating the obtained product of formula (I). The compound thus prepared may be recovered from the reaction mixture by conventional means. For example, the compounds may be recovered by distilling off the solvent from the reaction mixture or, if necessary after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract. Additionally, the product can, if desired, be further purified by various well known techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography.
Study of the biological properties of the derivatives of the invention showed an inhibitory activity vis-a-vis HIV integrase in vitro. Further experiments have also shown their inhibitory effect on the replication of HIV and the absence of effect on the late phases of the replication of HIV. These results are thus extremely interesting for the treatment of an infection by this virus, especially as the toxicity studies have shown the significant innocuity of these derivatives. The invention thus relates to pharmaceutical compositions characterized in that they contain an effective quantity of at least one derivative as defined above, in combination with pharmaceutically acceptable vehicles. In particular, the present invention concerns formulations of a compound of formula (I) suitable for oral administration. Said formulation may comprise one or more excipient(s) chosen from surfactant, emulsifier, solubility enhancers, etc...
The compounds of the invention are advantageously used in combination with other anti-viral agents, such as HIV medicaments, in particular medicaments endowed with an inhibitory effect vis-a-vis the integrase, reverse transcriptase and/or protease.
Such combinations are particularly advantageous in that the compounds of the invention are active on resistant viruses, in particular viruses resistant to reverse transcriptase inhibitors and/or to INSTI integrase inhibitors.
Further, such combinations are particularly advantageous in that they exhibit synergism.
The present invention thus also concerns such combinations of a compound of the invention with one or more integrase, reverse transcriptase and/or protease inhibitor(s), in particular, combinations of a compound of the invention with one or more INSTI inhibitor, such as raltegravir or elvitegravir.
The doses and administration methods are adapted as a function of the single-drug, two-drug or three-drug combination therapy treatment used. The invention also relates to the use of the derivatives defined above as biological reagents usable in particular for mechanism studies concerning the viral infection.
The identification of those subjects who are in need of treatment of herein- described diseases and conditions is well within the ability and knowledge of one skilled in the art. A clinician skilled in the art can readily identify, by the use of clinical tests, physical examination and medical/family history, those subjects who are in need of such treatment.
The compounds of the invention may be advantageously used for inhibiting INSTIs resistant integrase. A therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the therapeutically effective amount, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of subject; its size, age, and general health; the specific disease involved; the degree of involvement or the severity of the disease; the response of the individual subject; the particular compound administered; the mode of administration; the bioavailability characteristic of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
The amount of a compound of formula (I), which is required to achieve the desired biological effect, will vary depending upon a number of factors, including the dosage of the drug to be administered, the chemical characteristics (e.g. hydrophobicity) of the compounds employed, the potency of the compounds, the type of disease, the diseased state of the patient, and the route of administration.
In general terms, the compounds of this invention may be provided in an aqueous physiological buffer solution containing 0.1 to 10% w/v compound for parenteral and/or oral administration. Typical dose ranges are from 1 μg/kg to 0.1 g/kg of body weight per day; a preferred dose range is from 0.01 mg/kg to 10 mg/kg of body weight per day. A preferred daily dose for adult humans includes 1 , 5, 50, 100 and 200 mg, and an equivalent dose in a human child. The preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, and formulation of the compound excipient, and its route of administration.
The compounds of the present invention are capable of being administered in unit dose forms, wherein the term "unit dose" means a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described hereinafter. As such, typical daily dose ranges are from 0.01 to 10 mg/kg of body weight. By way of general guidance, unit doses for humans range from 0.1 mg to 1000 mg per day. Preferably, the unit dose range is from 1 to 500 mg administered one to four times a day, and even more preferably from 1 mg to 300 mg, once a day. Compounds provided herein can be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients. Such compositions may be prepared for use in oral administration, particularly in the form of tablets or capsules; or parenteral administration, particularly in the form of liquid solutions, suspensions or emulsions; or intranasally, particularly in the form of powders, nasal drops, or aerosols; or dermally, for example, topically or via trans-dermal patches or ocular administration, or intravaginal or intra-utehne administration, particularly in the form of pessaries or by rectal administration.
The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington: The Science and Practice of Pharmacy, 20th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000. Pharmaceutically compatible binding agents and/or adjuvant materials can be included as part of the composition. Oral compositions will generally include an inert diluent carrier or an edible carrier.
The tablets, pills, powders, capsules, troches and the like can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, or gum tragacanth; a diluent such as starch or lactose; a disintegrant such as starch and cellulose derivatives; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, or methyl salicylate. Capsules can be in the form of a hard capsule or soft capsule, which are generally made from gelatin blends optionally blended with plasticizers, as well as a starch capsule. In addition, dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents. Other oral dosage forms syrup or elixir may contain sweetening agents, preservatives, dyes, colorings, and flavorings. In addition, the active compounds may be incorporated into fast dissolve, modified-release or sustained-release preparations and formulations, and wherein such sustained-release formulations are preferably bi-modal.
Preferred formulations include pharmaceutical compositions in which a compound of the present invention is formulated for oral or parenteral administration, or more preferably those in which a compound of the present invention is formulated as a tablet. Preferred tablets contain lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or talc in any combination. It is also an aspect of the present disclosure that a compound of the present invention may be incorporated into a food product or a liquid. Liquid preparations for administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. The liquid compositions may also include binders, buffers, preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like. Non-aqueous solvents include alcohols, propylene glycol, polyethylene glycol, acrylate copolymers, vegetable oils such as olive oil, and organic esters such as ethyl oleate. Aqueous carriers include mixtures of alcohols and water, hydrogels, buffered media, and saline. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the release of the active compounds. Intravenous vehicles can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Other potentially useful parenteral delivery systems for these active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
Alternative modes of administration include formulations for inhalation, which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for buccal administration include, for example, lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate. Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate. Formulations for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which can be used include petroleum jelly, lanolin, polyethylene glycols, alcohols, or their combinations. Formulations suitable for transdermal administration can be presented as discrete patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive. Alternative administrations include also solutions, ointments or other formulations acceptable for ocular administration.
According to a particular aspect, the compound of the invention may be administered by the cutaneous, ocular or inhalation route as disclosed above.
These formulations are particularly advantageous as they ensure a local treatment, without associated lymphopenia which may occur with systemic administration routes.
FIGURES
Figure 1 illustrates the cross-resistance assay results obtained with a compound of the invention on INSTIs mutants.
Figure 2 illustrates the cross-resistance assay results obtained with a compound of the invention on RTIs mutants.
Other features of the invention will become apparent in the course of the following description of exemplary embodiments that are given for illustration of the invention and not intended to be limiting thereof.
EXAMPLES
- Example 1 : Synthesis of (E)-1-(2-(3-chloro-4,5-dihydroxystyryl)-8- hydroxyquinolin-5-yl)ethanone, also denoted 1-{2-[2(E)-(3-chloro, 4,5- dihydroxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl}-ethanone herein (SQE86):
First step : Preparation of : 1 -(8-hvdroxy-2-methylquinolin-5-yl)ethanone
To a solution of commercial 2-methylquinolin-8-ol (4.00 g, 25.13 mmol) in nitrobenzene (10 ml_) were added acetyl chloride (1 .96 ml_, 27.64 mmol) and aluminium chloride (8.38 g, 62.82 mmol). The reaction mixture was heated at 70°C overnight. After the mixture cooled, water and HCI 10% (10 ml_) were added with stirring, and reaction mixture was heated at 160°C, collecting nitrobenzene with a Dean-stark trap. After cooling and ethyl acetate washing, mixture was neutralized to pH 6-7 with NaOH. Aqueous phase was extracted with ethyl acetate, then organic layer was washed with brine, dried over MgSO4 and concentrated under vacuo. Crude product was purified by silica gel chromatography (cyclohexane /ethyl acetate 100:0 to 60/40) to give 1 -(8-hydroxy-2-methylquinolin-5-yl)ethanone as a pale yellow powder (3.51 g, 70%).
Second step: Preparation of (E)-1 -(2-(3-chloro-4,5-dihvdroxystyryl)-8- hvdroxyquinolin-5-yl)ethanone
To a solution of quinoline (0.300 g, 1 .49 mmol) in acetic anhydride (10 ml_) was added commercial aromatic aldehyde (0.772 g, 4.47 mmol). Mixture was heated in a sealed tube at 160°C for 16h and concen trated under vacuo. Residue was redissolved in a pyridine (10 ml_)/ water (5 ml_) mixture and heated at 130°C for 3 h . Solvents were evaporated and residue was purified by silica gel chromatography (ethyl acetate/cyclohexane 0:1 to 1 :0) to yield (E)-1 -(2-(3-chloro- 4,5-dihydroxystyryl)-8-hydroxyquinolin-5-yl)ethanone as a yellow solid (0.010 g, 2%).
Fp: 256°-258<C
ESI Mass : m/z 355.92 ([IVKH]+)
- Example 2 : Synthesis of (E)-5-(2-(5-acetyl-8-hydroxyquinolin-2-yl)vinyl)-2- hydroxybenzoic acid, also denoted 5-[2(E)-(5-Acetyl-8-hydroxy-quinolin-2-yl)- vinyl]-2-hydroxy-benzoic acid (SQE 89) :
First step : Preparation of : 1 -(8-hvdroxy-2-methylquinolin-5-yl)ethanone To a solution of commercial 2-methylquinolin-8-ol (4.00 g, 25.13 mmol) in nitrobenzene (10 ml_) were added acetyl chloride (1 .96 ml_, 27.64 mmol) and aluminum chloride (8.38 g, 62.82 mmol). The reaction mixture was heated at 70°C overnight. After the mixture cooled, water and HCI 10% (10 ml_) were added with stirring, and reaction mixture was heated at 160°C, collecting nitrobenzene with a Dean-stark trap. After cooling and ethyl acetate washing, mixture was neutralized to pH 6-7 with NaOH. Aqueous phase was extracted with ethyl acetate, then organic layer was washed with brine, dried over MgSO4 and concentrated under vacuo . Crude prod uct was pu rified by sil ica gel ch romatography (ethyl propionate/ethyl acetate 100:0 to 60/40) to give 1 -(8-hydroxy-2-methylquinolin-5- yl)ethanone as a pale yellow powder (3.51 g, 70%). Second step: Preparation of (E)-5-(2-(5-acetyl-8-hvdroxyαuinolin-2-yl)vinyl)-2- hydroxybenzoic acid
To a solution of quinoline (0.300 g, 1 .49 mmol) in acetic anhydride (15 ml_) was added commercial aromatic aldehyde (0.743 g, 4.47 mmol). Mixture was heated in a sealed tube at 160°C for 12 h and conce ntrated under vacuo. Residue was redissolved in a pyridine (10 ml_)/ water (10 ml_) mixture and heated at 110°C for 2h. Solvent were evaporated and residue was triturated with methanol, to give (E)-5-(2-(5-acetyl-8-hydroxyquinolin-2-yl)vinyl)-2-hydroxybenzoic acid (0.217 g, 41.79%) as a dark brown solid. Fp: 266<C-268<C ESI Mass : m/z 348.40 ([M+H]+)
The following compounds were also synthesized by application or adaptation of the procedures above, from the corresponding starting materials:
- 1 -{2-[2(E)-(2,3-Dihydroxy-4-methoxy-phenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone :
1 -{2-[2(E)-(2,4,5-thhydroxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl}-ethanone
1 -{2-[2(E)-(3,4,5-thhydroxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl}-ethanone
1 -{2-[2(E)-(3,4-dihydroxy, 5-nitrophenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone :
1 -{2-[2(E)-(4-hydroxy, 5-methoxy, 3-nitrophenyl)-vinyl]-8-hydroxy-quinolin-5- yl}-ethanone :
4-[2(E)-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-5-nitro-benzoic acid:
4-[(E)-2-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-3-nitro-benzoic acid methyl ester
3-[(E)-2-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-4-nitro-benzoic acid methyl ester:
5-[2(E)-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-2-hydroxy-4-nitro-benzoic acid :
1 -{2-[2(E)-(3-nitro, 4-hydroxy, 5-methoxyphenyl)-vinyl]-8-hydroxy-quinolin-5- yl}-ethanone :
1 -{2-[2(E)-(3,4-dihydroxy, 5-methoxyphenyl)-vinyl]-7-chloro, 8-hydroxy- quinolin-5-yl}-ethanone :
EXAMPLE 4 : Material & Methods and Results
1 -Biochemical activity assay
lntegrase Preparation and purification
The pET-15b-IN plasmid contains the cDNA encoding the HBX2 HIV integrase. His-tagged integrase protein was overexpressed in Escherichia coli BL21 (DE3) and purified under native conditions. Briefly, at an OD of 0.8, fusion protein expression was induced in bacterial cultures by the addition of IPTG (1 mM). Cultures were incubated for 3 h at 37O, af ter which cells were centhfuged. The cell pellet was resuspended in ice-cold buffer A [20 mM Ths-HCI (pH 8), 1 M NaCI, 4 mM β-mercaptoethanol, and 5 mM imidazole], treated with lysozyme for 1 h on ice, and sonicated. After centhfugation (30 min at 10 000 rpm), the supernatant was filtered (0.45 μm) and incubated for at least 2 h with Ni- NTA agarose beads (Pharmacia). The beads were washed twice with 10 volumes of buffer A, 10 volumes of buffer A with 50 mM imidazole, and 10 volumes of buffer A with 100 mM imidazole. His-tagged integrase was then eluted with buffer A supplemented with 50 μM ZnSO4 and 1 M imidazole. The integrase concentration was adjusted to 0.1 mg/mL in buffer A. The fusion protein was cleaved using thrombin and dialyzed overnight against 20 mM Ths-HCI (pH 8), 1 M NaCI, and 4 mM β-mercaptoethanol. After removal of biotinylated thrombin by incubation with streptavidin-agarose magnetic beads (Novagen, Madison, Wl), a second dialysis was performed for 2 h against 20 mM Ths-HCI (pH 8), 1 M NaCI, 4 mM β-mercaptoethanol, and 20% (v/v) ethylene glycol. Fractions were aliquoted and rapidly frozen at -80O.
Nucleic Acid Substrates
Oligonucleotides U5B (δ'-GTGTGGAAAATCTCTAGCAGT-S1), U5B-2 (51- GTGTGGAAAATCTCTAGCA-3'), U5A (δ'-ACTGCTAGAGATTTTCCACAC-S1) were purchased from Eurogentec (Liege, Belgium) and further purified on an 18% denaturing acrylamide/urea gel. For processing, strand transfer, 100 pmol of U5B, U5B-2, respectively, were radiolabeled using T4 polynucleotide kinase and 50 μCi of [γ-32P]ATP (3000 Ci/mmol). The T4 kinase was heat inactivated, and unincorporated nucleotides were removed using a Sephadex G-10 column (GE Healthcare). NaCI was added to a final concentration of 0.1 M, and complementary unlabeled strand U5A was added to either U5B or U5B-2. The mixture was heated to 90O fOr S min, and the DNA w as annealed by slow cooling. 3' LTR Processing Assays
Processing reaction was performed using U5A-U5B, in buffer containing
20 mM Tris (pH 7.2), 50 mM NaCI, 10 mM DTT, and 1OmM MgCI2. The reaction was initiated by addition of substrate DNA (12.5 nM), IN 20OnM and the mixture was incubated for up to 2 h at 37O. The reactions were stopped by phenol/chloroform extraction, and DNA products were precipitated with ethanol.
The products were separated in TE containing 7 M urea and electrophoresed on an 18% denaturing acrylamide/urea gel. Gels were analyzed using a STORM
Molecular Dynamics phosphorimager and quantified with Image Quant™ 4.1 software.
Strand Transfer Assays
Processing, strand transfer reactions were performed using U5A-U5B-2, in buffer containing 20 mM Tris (pH 7.2), 50 mM NaCI, 10 mM DTT, 1 OmM MgCI2. The reaction was initiated by addition of substrate DNA (12.5 nM), IN 20OnM and the mixture was incubated for up to 2 h at 37O. Th e reaction was stopped by phenol/chloroform extraction, and DNA products were precipitated with ethanol.
The products were separated in TE containing 7 M urea and electrophoresed on an 18% denaturing acrylamide/urea gel. Gels were analyzed using a STORM Molecular Dynamics phosphorimager and quantified with Image Quant™ 4.1 software.
2 - Stability assays Two protocols were carried out:
2.1. Hepes Buffer 0.5M, pH 7.5. 16 μl of drug at 25 mM, in 8 ml of Hepes Buffer. Different time points were done, Oh, 2h, 4h, 24h, and 48h.
Stability of the compounds was performed in HEPES Buffer 0.5 M (pH 7.5) at 37O, at a concentration of 50 μM. Compounds SQE94 and 79 were tested at a concentration of 25 μM to avoid parasite precipitation phenomena. Typically, stock solutions of compounds in DMSO (25 mM) were diluted in HEPES Buffer. Dilutions were stored at 37O, protected from light. Sampling was done at different time points. Samples were analyzed on an UV-spectrophotometer using a wavelength scan between 200 and 700 nm. Superposition of UV-spectra gives the qualitative aspect of the stability of the drug. Based on the Beer-Lambert law, percentage of degradation of the drug over time was calculated, when placed at the maximum absorption wavelength. Results are summarized below :
% of degradation
Compound λmax (nm) 0 2 hrs 4 hrs 24 hrs
SQE74 307 n/a 17,2 26,1 24,1
SQE75 322 n/a 15,7 17,5 18,7
SQE79 360 n/a 19,2 26,9 42,9
SQE86 356 n/a 12,1 12,5 22,4
SQE89 321 n/a <5 <5 <5
SQE94 369 n/a <5 8,2 30,8
SQE96 299 n/a <5 <5 <5
FZ41 332 n/a 31 ,1 59,6 64,6
These results show that the compounds of the invention show an improved compared to compound FZ41 of the prior art (WO 98/45269) which shows a poor stability.
2.2. The second stability assay consists in the assessment according to standard HPLC analysis protocols over 24 hrs in PEG400 and Vitamine E- TPGS/PEG 400 mixtures, by focusing on the evolution of the concentration and peak purity of the compound.
Compounds were dissolved in appropriate amounts of solvent and let under stirring protected from light for 24 hrs. Aliquots were transferred into eppendorfs and centhfuged at 10 000 g for 10 min. Supernatants were collected and appropriately diluted in DMSO/ mobile phase mixtures before HPLC analysis. The Waters HPLC analysis system equipped with an ultraviolet detector and a Waters Symmetry Shield C18 column of 2.1 mm x 50 mm (3.5 μM) was used. A mobile phase of water/acetic acid 0.1 % (Solvant A) : Acetonitrile/acetic acid 0.1 % (solvent B) mixture or a water/trifluoroacetic acid 0.1 % (Solvant A) : Acetonitrile/ trifluoroacetic acid 0.1 % (solvent B) mixture in the case of compound FZ41 was pumped according to a binary gradient described below, at a flow rate of 0.4 ml/min.
Results are summarized below: Compound SQE94:
Compound FZ41 (WO98/45269):
The compounds of the invention, and more particularly compound SQE94, demonstrated high stability over 24 hrs at room temperature in several mixtures of excipients with less than 10% degradation, whereas FZ41 exhibited at least 10% degradation within only 3 hrs, as stated by the apparition of impurity peaks.
Moreover, the compounds and more particularly compound SQE94, exhibited very stable chemical profiles over 24 hrs at pH comprised between 1 and 7, whereas FZ41 degradated at rates reaching 50-60% within less than 24 hrs. 3-Antiviral & viability assays Viability assay
The cytotoxicity of compounds was evaluated using un-infected and infected Hel_a-P4 cell and CEM leukemia cells. CEM cell were obtained from the American Type Tissue Collection (Rockville, MD).
A serial dilution of drugs is done to evaluate the cytotoxicity concentration and is identified by CC50 (concentration of drug which induces 50% of cytotoxicity)
The Hel_a-P4 was cultured in the presence or absence of compounds for 2 days. After this time period, cells were cultivated with MTT for 3 hours, further the medium is removed. And the lysis buffer is incubated for 1 hour, followed by plate reading at 540 nm in a microplate reader.
Antiviral activity assay on HeIa P4 cells
The antiviral activity is determined by infecting HelaP4 cells with a wild type HIV-1 virus (NL 4.3 strains at 3ng) on cells in presence or absence of drugs.
A serial dilution of drugs is done to evaluate the EC50. The effective concentration is the concentration of product at which virus replication is inhibited by 50 percent.
After 48 hours incubation, the quantification is done by the evaluation of β- Galactosidase produced by the infected HeIa P4 cells. The viral activity is evaluated by colorimethc assay, CPRG, followed by plate reading at 570 nm with a reference of 690 nm. The CPRG test is a colohmetric assay which allows to quantity the β-galactosidase produced by HIV-1 infected indicator cells (the β-Gal gene being under the control of the HIV-1 LTR).
Antiviral activity assay CEM cells
The activity is determined by infecting CEM cells with a wild type HIV-1 virus (NL 4.3 strains at 3ng) on cells in presence or absence of drugs.
A serial dilution of drugs is done to evaluate the EC50. The effective concentration is the concentration of product at which virus replication is inhibited by 50 percent.
After 48 hours incubation, the quantification is done by the evaluation of the viral protein p24 with a commercial Elisa Kit. P24 is a protein essential to the replication virus cycle. The quantification of this enzyme is proportional to the amount of virus produced by the infected cells.
A summary of results obtained in Biochemical activity, and Antiviral & viability assays is showed below:
As a comparative example, the following FZ41 compound representative for compounds disclosed in WO98/45269 was also tested, as shown below :
It is apparent from the results above that the compounds of the invention are more active than those of the prior art, in particular during the first step (3' processing), and the second step (strand transfert step).
4-Cross-Resistance assay
Antiviral products targeting the same protein (typically products of the same drug class) may develop mutations that lead to reduced susceptibility to one antiviral product and can result in decreased or loss of susceptibility to other antiviral products in the same drug class. This observation is referred to as cross- resistance. Cross-resistance is not necessarily reciprocal, so it is important to evaluate the activity of our new compounds on viruses containing mutations observed with other drugs of the anti-integrase class or reverse transcriptase inhibitors (RTI) class. Mutant viruses which are Raltegravir & Elvitegravir resistant were constructed on the NL43 backbone. Mutants viruses were as followed, where the first letter corresponds to the wild type amino acid, the number corresponds to the position of the amino acid in the integrase sequence and the second letter corresponds to the mutated amino acid. NL4.3 E92Q,
NL4.3 G140S, NL4.3 Q148H, NL4.3 N155H, NL4.3 E92Q+ N155H, NL4.3 G140S/ Q148H.
Resistant mutant viruses of RTI are known and include K103N, Y178L, Y181 C, G190A, V108I/Q151 M, K103N/G190A, K103N/Y188C, K103N/Y181 C, M41 L/T215Y/K103N, M41 L/T215Y/Y181 C, M41 L/T215Y/M184V.
The assay to evaluate the activity against resistant viral strains is the same that antiviral assay. Instead of using a Wild-type virus, the virus studied contains mutations. The results are presented as a fold change corresponding to the ratio between the IC50 obtained for the mutant virus and the IC50 obtained for the wild type virus. More the virus is resistant to the compound more the fold change is elevated. If the mutation has no impact on the activity of the drug, the fold change is around 1.
The results obtained with the SQE94 compound of the invention on INSTIs mutants are illustrated on Figure 1. The results obtained with the SQE94 compound of the invention on RTIs mutants, compared to common RTIs are illustrated on Figure 2.
5 - Synergism with other anti-viral compounds
A combination manifests therapeutic synergy if it is therapeutically superior to the addition of the therapeutic effects of the independent constituents. The efficacy of a combination may be demonstrated by comparing the IC50 values of the combination with the IC50 values of each of the separate constituents in the study in question. This efficacy may be readily determined by the one skilled in the art. From the IC50 values, a combination index (Cl) may be calculated, for instance using the computer program CalcuSyn software from Biosoft, for inhibition efficiencies of 50%, 75% or 90%. The program CalcuSyn performs multiple drug dose-effect calculations using the Median Effect methods described by Chou et al Trends Pharmacol. Sci. 4:450-454, 1983 and Chou et al Enzyme Regul. 22, 27-55, 198', which are incorporated herein by reference.
The combination index (Cl) equation is based on the multiple dose effect equation of Chou et al derived from enzyme kinetics model. The synergism is defined as a more than expected additive effect and antagonism as a less than expected additive effect. Chou et al proposed the designation of Cl=1 as the additive effect. Thus from the multiple drugs effect equation of two drugs, for mutually non exclusive drugs that have totally independent modes of action, Cl is calculated as follows:
Cl= [(D1 )/(Dx1 )] + [(D2)/(Dx2)] + [(D1 D2)/(Dx1 Dx2 )]
In the equation, (D1 ) and (D2) are the concentrations of drug 1 and 2, respectively, for which x % of inhibition is obeyed in the drug combination. (Dx1 ) and (Dx2) are the concentrations of drug 1 and 2 respectively for which x % of inhibition is obeyed for drugs alone.
Cl<1 , =1 and > 1 respectively indicates synergism, additive effect and antagonism. Compounds of the invention (SQE94) show synergism with INSTI :
Synergistic interactions between compounds of the invention (SQE94) and INSTI (Raltegravir or RGV) were investigated using a NL43 HIV-1 laboratory strain replication assay. Virus infectivity in the presence of inhibitors was monitored with HelaCD4+β-Gal indicator cells (P4 cells). Inhibition by combination of SQE94 and INSTI was evaluated at two fixed molar SQE94/ INSTI ratios: (i) 100:1 when the combination is tested on wild type virus and (ii) 6:1 when the combination is tested on INSTI resistant virus.
Interactions were calculated by the multiple drug effect equation of Chou et al
1983 and 1984 (supra) based on the median effect principle, using CalcuSyn® software (Biosoft, UK). Efficacy of drug combination was given by the combination index for the inhibition efficiencies of 50%, 75% and 90%. At a given effective dose, drugs were classically considered synergistic when the combination index was < 1 and antagonistic when combination index was > 1.
Material and Methods
Step 1: preparation of HeLa P4 cells in a 96 flat bottom well plate
Two days before the test, 4000 HeLa P4 cells per well are seeded in 100μl of 10% FBS DMEM supplemented with 100UI/ml penicillin, 100μg/ml streptomycin and 0.5 mg/ml geneticin (G418).
One plate is used for the 2 drugs alone. Half a plate is used for the combination between the two drugs. The cytotoxicity of the drugs alone and the combination is tested by MTT assay.
Step 2: Drug dilution
The dilutions tested for the "Wild type" virus are as follows: 16IC5o -> 8IC50 ^4IC50 ^2IC50 -÷1 IC50 ■* ICso/2^ IC50M-* IC50/8^ IC50/16^ IC50/32 Drugs alone :
INBI (SQE94) ALONE
ICso/32 IC50/I6 IC50/8 ICso/4 ICso/2 1 IC50 2IC50 4IC50 8IC50 16IC50
r,. . Virus Blank . ICso/32 IC50/I6 IC50/8 ICso/4 ICso/2 alone 1 IC50 2IC50 4IC50 8IC50 16IC50
ICso/32 IC50/I6 IC50/8 ICso/4 IC50/2 1 IC50 2IC50 4IC50 8IC50 I 6IC50
ICso/32 IC50/I6 IC50/8 ICso/4 IC50/2 1 IC50 2IC50 4IC50 8IC50 16IC50
oi i Virus B ank . abne ICso/32 IC50/I6 IC50/8 ICso/4 IC50/2 1 IC50 2IC50 4IC50 8IC50 16IC50
ICso/32 IC50/I6 IC50/8 ICso/4 ICso/2 1 IC50 2IC50 4IC50 8IC50 16IC50
INSTI (RGV) ALONE
Combination SQE94 + RGV :
INBI (SQE94)/ INSTI (RGV) Combination
ICso/32 IC50/16 IC50/8 ICso/4 IC50/2 ICso/4 2IC50 4IC50 8IC50 16IC50 Drug1 + Drug1 + Drug1 + Drug1 + Drug1 - H Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + ICso/32 IC50/I 6 IC50/8 ICso/4 IC50/2 ICso/4 2IC50 4IC50 8IC50 16IC50 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2
ICso/32 IC50/I 6 IC50/8 ICso/4 IC50/2 IC50 2IC50 4IC50 8IC50 16IC50 Drug1 + Drug1 + Drug1 + Drug1 - H Drug1 + Drug1 + Drug1 + Drug1 + Drug1 +
Blank VirUS Drug 1 + blanκ alone IC50/32 IC50/I 6 IC50/8 ICso/4 IC50/2 IC50 2IC50/4 4IC50 8IC50 16IC50
Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2
ICso/32 IC50/I 6 IC50/8 ICso/4 IC50/2 ICso/4 2IC50 4IC50 8IC50 16IC50 Drug1 + Drug1 + Drug1 + Drug1 + Drug1 - H Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + ICso/32 IC50/I 6 IC50/8 ICso/4 IC50/2 ICso/4 2IC50 4IC50 8IC50 16IC50 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2
The dilutions tested for the "INSTI's Mutants" virus are as follows: 60IC50 -» 20IC50 ^6,7IC50 ^2,2IC50 ^0,74IC50 -» 0.25IC50^ 0.08IC50^ 0.03IC50^ 0.009IC50^ 0.003IC50
Combination SQE94 + RGV :
INBI (SQE94)/ INSTI (RGV) Mix
0.003IC50 0.009IC50 0.03IC50 0.081 IC50 0.25IC50 0.741 IC50 2.2IC50 6.71 IC50 20IC50 60IC50 Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + 0.003IC50 0.009IC50 0.03IC50 0.081 IC50 0.25IC50 0.741 IC50 2.2IC50 6.71 IC50 20IC50 60IC50 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2
0.003IC50 0.009IC50 0.03IC50 0.081 IC50 0.25IC50 0.741 IC50 2.2IC50 6.71 IC50 20IC50 60IC50Dr
Virus Dm91 + Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + ug1 + Blank ^ 0.003IC50 0.009IC50 0.03IC50 0.081 IC50 0.25IC50 0.741 IC50 2.2IC50 6.71 IC50 20IC50 60IC50
Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2
0.003IC50 0.009IC50 0.03IC50 0.081 IC50 0.25IC50 0.741 IC50 2.2IC50 6.71 IC50 20IC50 60IC50 Drug1 + Drug1 + Drug1 + Drug1 + Drug1 + Drug1 +0. Drug1 + Drug1 + Drug1 + Drug1 +
0.003IC50 0.009IC50 0.03IC50 0.081 IC50 0.25IC50 741 IC50 2.2IC50 6.71 IC50 20IC50 60IC50 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2 Drug2
Combination index for the combination SQE94 + RGV :
The combinations of the compounds of the invention with an INSTI show synergism on wild type viruses and INSTI resistant viruses.
6- Formulations of the compounds of the invention
Quinoline derivatives may present a low solubility in aqueous buffers at pH 5, 6 and 7. Two formulations were identified to solve this drawback:
Formulation A: Tween 80/Labrafac® Lipophile/DMSO: 65/25/10 Formulation B: Tween 80/Labrafil ® M1944 CS/DMSO: 65/25/10
Labrafil® and Labrafac® are solubility enhancers; Labrafil® M1944 CS comprises Oleoyl Macrogolglycerides (Polyoxylglycehdes) and Labrafac® Lipophile is a mixture of Medium Chain Triglycerides.
Tween 80, Labrafac™ Lipophile WL 1349 and Labrafil M1944 CS are purchased from Gattefosse (France).
Solubility of compound SQE94 in pH-buffers and formulations
Solubility of compound SQE94 was determined in pH-buffers at pH values of 5, 6 and 7. 10 mg of SQE94 are added to 10 ml of each pH-buffer. Each solution is stirred at room temperature, away from light, for 24h, then centrifugated. The amount of dissolved compound is determined by HPLC analysis.
Solubility of compound SQE94 was determined in formulation A and B. 50 mg of product is dissolved in 5 mL of formulation and stirred at 37O for 24h, then centrifugated. The amount of dissolved compound is determined by HPLC analysis.
Dilution of formulated compound in pH-buffers at pH 5, 6 and 7.
Formulated compound SQE94 (in formulation A or B) is diluted 1/10e with 37O pH-buffers (pH 5,6 and 7). Samples are immedia tely collected and centhfuged. The amount of dissolved compound is determined by HPLC analysis.
Material :
Formulation A and B enable to increase the solubility of compound SQE94 at pH 5, 6 and 7 by at least a 80-fold. These pHs mimic the pH within the intestinal tractus, where the maximum of absorption of a drug takes place. Results are summarized in following table : Dissolved Dompound SQE94 (μg/ml)
P H 5 p H 6 P H 7
C O m P O U n d a o n e 1 . 4 1 . 4 5 5
F O r m U I a t i O n A 4 7 0 5 4 0 4 5 0
F O r m U I a t i O n B 4 1 0 5 6 0 4 5 0
Formulations A and B show good solubility, suitable to oral formulation of quinoline derivatives of the invention.
Further tests were conducted on the compounds of the invention, including Log D determination, and Absorption, Distribution, Metabolism and Excretion (ADME), These tests confirmed the drug candidate profile of quinoline derivatives of the invention.

Claims

1. A compound of general formula (I):
(I) wherein :
- R1 , R2, R4, R5, R6, R7, R8 identical or different, independently represent a hydrogen atom or a group chosen from -(CH2)n-Y or -CH=CH-Y, where Y represents a halogen atom, -OH, -OR, -COH, -COR, -COOH, -COOR, -CONH2, -CON(Rx1Ry), -CH=NOH, -CO-CH=NOH, -NH2, -N(Rx1Ry), -NO2, -PO(OR)2, -PO(OH)2, -C(=O)-NH-OH, -SH2, -SR, -SO2R, -SO2NHR, CN,
- X represents a group chosen from -(CH2)n-Y or -CH=CH-Y, where Y represents -OH, -OR, -COH, -COR, -CONH2, -CON(Rx1Ry), -CH = NOH, -CO- CH=NOH, -NH2, -N(Rx1Ry), -PO(OR)2, -PO(OH)2, -C(=O)-NH-OH, -SH2, -SR, -SO2R, -SO2NHR, CN, where R represents an alkyl, or an aryl or heterocycle, Rx and Ry, identical or different represent an alkyl, and n is an integer chosen from O, 1 to 5; as well as their pharmaceutically acceptable salts, their diastereoisomers and enantiomers.
2. A compound according to claim 1 , wherein X represents a group chosen from a halogen atom, -OH, -OR, -COH, -COR, CN.
3. A compound according to claim 1 or 2, wherein X represents -COR or -
OH.
4. A compound according to claim 1 , 2 or 3, wherein R1 and R2 are H.
5. A compound according to anyone of claims 1 to 4, wherein R1 , R2, R3, R4, R5, R6, R7 identical or different, independently represent a hydrogen atom or a halogen atom or a group chosen from -OH, -OR, -COH, -COR, -COOH, -COOR, -NO2, -PO(OR)2, -PO(OH)2, -C(=O)-NH-OH, CN.
6. A compound according to anyone of claim 1 to 5, wherein R1 , R2, R3, R4, R5, R6, R7, identical or different, are chosen from a hydrogen atom, or a group chosen from -OH, -COR, -COOH, -NO2
7. A compound according to anyone of claims 1 to 6, wherein at least one of R4, R5, R6, R7, Rδ is OH.
8. A compound according to anyone of claim 1 to 7, wherein R6 is OH.
9. A compound according to claim 1 to 8 chosen from :
- 1 -{2-[2(E)-(3-chloro, 4,5-dihydroxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone;
- 5-[2(E)-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-2-hydroxy-benzoic acid ;
- 1 -{2-[2(E)-(2,3-Dihydroxy-4-methoxy-phenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone;
- 1 -{2-[2(E)-(2,4,5-thhydroxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl}-ethanone; - 1 -{2-[2(E)-(3,4,5-thhydroxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl}-ethanone ;
- 1 -{2-[2(E)-(3,4-dihydroxy, 5-nitrophenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone ; - 1 -{2-[2(E)-(4-hydroxy, 5-methoxy, 3-nitrophenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone ;
- 4-[2(E)-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-5-nitro-benzoic acid;
- 4-[(E)-2-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-3-nitro-benzoic acid methyl ester ; - 3-[(E)-2-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-4-nitro-benzoic acid methyl ester; - 5-[2(E)-(5-Acetyl-8-hydroxy-quinolin-2-yl)-vinyl]-2-hydroxy-4-nitro-benzoic acid ;
- 1 -{2-[2(E)-(3-nitro, 4-hydroxy, 5-methoxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl}- ethanone ;
- 1 -{2-[2(E)-(3,4-dihydroxy, 5-methoxyphenyl)-vinyl]-7-chloro, 8-hydroxy-quinolin-5- yl}-ethanone ; as well as their pharmaceutically acceptable salts, their diastereoisomers and enantiomers.
10. Process of preparation of a compound according to anyone of claims 1 to 9 comprising the reaction of a corresponding quinaldine of formula (II):
with a compound of formula
(III) where RV, R2\ R4\ R5\ R6\ R7\ R8\ X' are defined as R1 , R2, R4, R5,
R6, R7, R8, X in anyone of the preceding claims, provided any reactive function present in R1 , R2, R4, R5, R6, R7, R8, X may be protected by an appropriate protective group in RV, R2', R4\ R5\ R6\ R7', R8\ X' respectively, and where Pg denotes either H or a protective group of the OH function if required, followed by the deprotection of any protective group present as appropriate.
1 1 . A pharmaceutical composition comprising a compound of formula (I) according to anyone of claims 1 to 9 with a pharmaceutical acceptable carrier.
12. The pharmaceutical composition according to claim 11 suitable for oral administration.
13. A compound of formula (I) according to anyone of claims 1 to 9 for the treatment and/or prevention of HIV.
14. A compound of formula (I) according to anyone of claims 1 to 9 for inhibiting integrase.
15. A compound of formula (I) according to anyone of claims 1 to 9 for inhibiting INSTIs resistant integrase.
16. A combination comprising a compound according to anyone of claims 1 to 9 and an anti-viral agent.
17. The combination according to claim 16, wherein said anti-viral is chosen from anti-integrase inhibitors and/or reverse transcriptase inhibitors.
EP09780982A 2008-07-23 2009-07-23 Styrylquinolines, their process of preparation and their therapeutic uses Withdrawn EP2303844A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09780982A EP2303844A1 (en) 2008-07-23 2009-07-23 Styrylquinolines, their process of preparation and their therapeutic uses

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08161000A EP2147912A1 (en) 2008-07-23 2008-07-23 Styrylquinolines, their process of preparation and their therapeutic uses
US12/269,241 US20100120847A1 (en) 2008-11-12 2008-11-12 Styrylquinolines, their process of preparation and their therapeutic uses
EP09305237 2009-03-13
PCT/EP2009/059494 WO2010010149A1 (en) 2008-07-23 2009-07-23 Styrylquinolines, their process of preparation and their therapeutic uses
EP09780982A EP2303844A1 (en) 2008-07-23 2009-07-23 Styrylquinolines, their process of preparation and their therapeutic uses

Publications (1)

Publication Number Publication Date
EP2303844A1 true EP2303844A1 (en) 2011-04-06

Family

ID=41131767

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09780982A Withdrawn EP2303844A1 (en) 2008-07-23 2009-07-23 Styrylquinolines, their process of preparation and their therapeutic uses

Country Status (2)

Country Link
EP (1) EP2303844A1 (en)
WO (1) WO2010010149A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835426B2 (en) 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
AR069207A1 (en) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc CYCLIC UREAS AS INHIBITORS OF THE 11 BETA - HIDROXI-ESTEROIDE DESHIDROGENASA 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
JP5301563B2 (en) 2008-05-01 2013-09-25 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1
TW201016691A (en) 2008-07-25 2010-05-01 Boehringer Ingelheim Int Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
NZ590495A (en) 2008-07-25 2012-10-26 Vitae Pharmaceuticals Inc Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2744946A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
UA109255C2 (en) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5813106B2 (en) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Azaspirohexanone as an inhibitor of 11-β-HSD1 for the treatment of metabolic disorders
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
CN102924374B (en) * 2012-02-15 2014-04-16 湖北欣瑞康医药科技有限公司 Preparation method for quinoline-4-carboxylic acid derivative
US10041408B2 (en) * 2015-02-13 2018-08-07 United Technologies Corporation Turbine engine with a turbo-compressor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1902595A1 (en) * 1969-01-20 1970-08-13 Soc D Etudes Prod Chimique 2-methyl-5-nitro-8-hydroxyquinoline derivs antiparasitic
WO2006129134A1 (en) * 2005-06-01 2006-12-07 Bioalliance Pharma Synergic combinations comprising a styrylquinoline compound and other hiv infection therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010010149A1 *

Also Published As

Publication number Publication date
WO2010010149A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
US20110224242A1 (en) Styrlyquinolines, their process of preparation and their therapeutic uses
EP2303844A1 (en) Styrylquinolines, their process of preparation and their therapeutic uses
JP4405602B2 (en) Histone deacetylase inhibitor
TWI580668B (en) Hepatitis b antiviral agents
US6670377B1 (en) Quinoline derivatives, having in particular antiviral properties, preparation and biological applications thereof
US11555026B2 (en) AHR inhibitors and uses thereof
TW200831085A (en) Non-nucleoside reverse transcriptase inhibitors
TW201022216A (en) Compounds, compositions and methods of using same for modulating uric acid levels
US20140094485A1 (en) Solid state forms of hiv inhibitor
CN111662281B (en) Salicylic acid berberine type alkaloid quaternary ammonium salt and application thereof in preparing medicines
AU2007275689A1 (en) AZA-peptide protease inhibitors
WO2013075596A1 (en) Pentabasic dihydrogen heterocyclic ketone derivative as dhodh inhibitor and use thereof
WO2015000431A1 (en) Tizoxanide carbamate and pharmaceutical use thereof
CA3124852A1 (en) Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases
JP6373297B2 (en) 1,3-Dioxoindene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof and pharmaceutical composition containing it as an antiviral active ingredient
US7863323B1 (en) Flavonols
WO2010010148A1 (en) Styrylquinolines, their process of preparation and their therapeutic uses
CN110407765A (en) 1,2,5- furodiazole derivative, preparation method and its application in medicine
WO2014012467A1 (en) Diarylaniline or diarylpyridinamine compound and preparation method and medical use thereof
WO2010010147A1 (en) Styrylquinolines, their process of preparation and their therapeutic uses
US20100120847A1 (en) Styrylquinolines, their process of preparation and their therapeutic uses
JPS6232170B2 (en)
US7064133B2 (en) Quinoline derivatives process of synthesis and medicaments containing these derivatives
EP2147912A1 (en) Styrylquinolines, their process of preparation and their therapeutic uses
CN112204035A (en) Substituted 3,4,12,12 a-tetrahydro-1 n1- [1,4] oxazino [3,4-c ] pyrido [2,1-f ] [1,2,4] triazine-6, 8-diones, pharmaceutical compositions, methods of production and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130201